Search

Home > ACC CardiaCast > ACC CardiaCast: Which Patients Can Benefit from the Newly-Approved Cardiac Myosin Inhibitor Recently Approved for HCM
Podcast: ACC CardiaCast
Episode:

ACC CardiaCast: Which Patients Can Benefit from the Newly-Approved Cardiac Myosin Inhibitor Recently Approved for HCM
Category: Science & Medicine
Duration: 00:13:40
Publish Date: 2022-05-27 16:15:00
Description:

In this episode, Drs. Matt Martinez and Sara Saberi discuss the recent approval by the FDA of the cardiac myosin inhibitor Mavacamten for the treatment of hypertrophic cardiomyopathy, and what sorts of patients are best suited for this treatment.
Total Play: 0